Tdap Vaccination 2 Weeks Before Delivery
Yes, administering Tdap vaccine at least 2 weeks before delivery is both safe and recommended, though ideally it should be given earlier in the third trimester (between 27-36 weeks gestation) to maximize antibody transfer to the infant. 12
Optimal Timing and Rationale
The ACIP guidelines explicitly state that optimal timing for Tdap administration is between 27 and 36 weeks gestation, though the vaccine may be given at any time during pregnancy 111. The biological rationale for this window is critical:
- A minimum of 2 weeks is required to mount a maximal immune response to vaccine antigens 11
- Active transport of maternal IgG across the placenta does not substantially occur before 30 weeks gestation 11
- Maternal antibodies wane quickly—even women vaccinated in the first or second trimester have low antibody levels at term 11
Therefore, vaccination 2 weeks before delivery (approximately 38 weeks) is acceptable and will provide protection, but earlier vaccination in the 27-36 week window is preferable to optimize maternal antibody response and maximize passive transfer to the infant.
Safety Profile
The safety data are robust and reassuring:
- A large cohort study of 16,606 Tdap recipients showed no increased risks of preterm delivery, small for gestational age, stillbirth, or neonatal death 3
- No evidence of major birth defects associated with Tdap exposure in any trimester 4
- Systematic review of 21 studies found no clinically significant harms to fetus or neonate 5
- The FDA label confirms safety for third-trimester administration 2
Effectiveness
Tdap vaccination during the third trimester is highly effective at preventing pertussis in infants younger than 2 months:
- Vaccine effectiveness of 77.7% (95% CI: 48.3-90.4%) against pertussis in infants <2 months 6
- Effectiveness increases to 90.5% (95% CI: 65.2-97.4%) against hospitalized cases 6
- FDA Bayesian meta-analysis estimates effectiveness of 81.5-83.4% depending on prior weighting 2
Clinical Implementation
Administer Tdap during each pregnancy, regardless of prior vaccination history 17:
- Give as a single 0.5 mL intramuscular injection in the deltoid muscle 2
- If a patient presents at 38 weeks without prior Tdap, vaccinate immediately—the 2-week window before delivery still provides meaningful protection
- If not given during pregnancy, administer immediately postpartum 11
Important Caveats
One consideration: Maternal vaccination may result in slightly diminished infant antibody responses to their own DTaP series 2, though the clinical significance of this blunting effect is unknown and does not outweigh the substantial benefit of protecting vulnerable newborns during their first 2 months of life when pertussis mortality is highest.
The recommendation is unequivocal: vaccinate during every pregnancy, ideally between 27-36 weeks, but do not withhold if presenting later—even 2 weeks before delivery provides critical protection.